These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 4184995)

  • 1. Complement.
    Müller-Eberhard HJ
    Annu Rev Biochem; 1969; 38():389-414. PubMed ID: 4184995
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of multivalent complexes formed in the presence of more than one conventional antibody to terminal complement component C5.
    Cone J; Kimmel L; Zhang Y; Johnson K; Sheridan D; Tamburini P
    PLoS One; 2023; 18(4):e0284502. PubMed ID: 37079521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group IIA-Secreted Phospholipase A
    Paganelli FL; Leavis HL; He S; van Sorge NM; Payré C; Lambeau G; Willems RJL; Rooijakkers SHM
    Infect Immun; 2018 Aug; 86(8):. PubMed ID: 29784864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TSLP-complement axis mediates neutrophil killing of methicillin-resistant
    West EE; Spolski R; Kazemian M; Yu ZX; Kemper C; Leonard WJ
    Sci Immunol; 2016 Nov; 1(5):. PubMed ID: 28783679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C5a induces caspase-dependent apoptosis in brain vascular endothelial cells in experimental lupus.
    Mahajan SD; Tutino VM; Redae Y; Meng H; Siddiqui A; Woodruff TM; Jarvis JN; Hennon T; Schwartz S; Quigg RJ; Alexander JJ
    Immunology; 2016 Aug; 148(4):407-19. PubMed ID: 27213693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exopolysaccharides isolated from hydrothermal vent bacteria can modulate the complement system.
    Courtois A; Berthou C; Guézennec J; Boisset C; Bordron A
    PLoS One; 2014; 9(4):e94965. PubMed ID: 24736648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation.
    Girard-Pierce KR; Stowell SR; Smith NH; Arthur CM; Sullivan HC; Hendrickson JE; Zimring JC
    Blood; 2013 Sep; 122(10):1793-801. PubMed ID: 23878139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance.
    Yu H; Muñoz EM; Edens RE; Linhardt RJ
    Biochim Biophys Acta; 2005 Nov; 1726(2):168-76. PubMed ID: 16125850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antigenic and molecular alterations of C3 in the fluid phase during an immune reaction in normal human serum. Demonstration of a new conversion product, C3x.
    Spitzer RE; Stitzel AE; Pauling VL; Davis NC; West CD
    J Exp Med; 1971 Sep; 134(3 Pt 1):656-80. PubMed ID: 15776568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assembly of the functional membrane attack complex of human complement: formation of disulfide-linked C9 dimers.
    Ware CF; Kolb WP
    Proc Natl Acad Sci U S A; 1981 Oct; 78(10):6426-30. PubMed ID: 6796960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic measurement of the interaction of rheumatoid factor with IgG-coated latex particles and the influence of the first component of human complement.
    Hällgren R
    Clin Exp Immunol; 1980 Jan; 39(1):154-63. PubMed ID: 6771071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of prostacyclin (PGI2) on immune-complex-induced neutropenia.
    Camussi G; Bussolino F; Tetta C; Caligaris Cappio F; Coda R; Macchiorlatti E; Alberton M; Roffinello C; Segoloni G
    Immunology; 1983 Apr; 48(4):625-33. PubMed ID: 6339375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [C1-inactivator from guinea pig-serum mechanism of action. II. Effect of the inactivator on C1 in its bound form: EAC1, EAC14b and EAC14b2a].
    Loos M
    Z Med Mikrobiol Immunol; 1971; 156(2):221-32. PubMed ID: 5554814
    [No Abstract]   [Full Text] [Related]  

  • 14. The reaction mechanism of human C5 in immune hemolysis.
    Cooper NR; Müller-Eberhard HJ
    J Exp Med; 1970 Oct; 132(4):775-93. PubMed ID: 5508377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysis of erythrocytes by complement in the absence of antibody.
    Götze O; Müller-Eberhard HJ
    J Exp Med; 1970 Nov; 132(5):898-915. PubMed ID: 5470509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of arginine and tyrosine esterase in serum from patients with hereditary angio-oedema.
    Eisen V; Loveday C
    Br J Pharmacol; 1972 Sep; 46(1):157-66. PubMed ID: 5084818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of the membrane attack mechanism of complement.
    Kolb WP; Haxby JA; Arroyave CM; Müller-Eberhard HJ
    J Exp Med; 1972 Mar; 135(3):549-66. PubMed ID: 5058233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The concentrations of the fourth component of complement and of the C1 inactivator in synovial fluid from arthritic patients.
    Hedberg H; Laurell AB
    Clin Exp Immunol; 1972 Jun; 11(2):201-7. PubMed ID: 5040309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suramin--a potent reversible and competitive inhibitor of complement systems.
    Fong JS; Good RA
    Clin Exp Immunol; 1972 Jan; 10(1):127-38. PubMed ID: 5017365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of human C1q. Studies in hypogammaglobulinemia, myeloma, and systemic lupus erythematosus.
    Kohler PF; Müller-Eberhard HJ
    J Clin Invest; 1972 Apr; 51(4):868-75. PubMed ID: 5014614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.